Chong Kun Dang Begins First U.S. Patient Enrollment for Global Clinical Trial of ADC Anticancer Drug

Phase 1/2 Clinical Trial for Patients with Non-Small Cell Lung Cancer and Various Solid Tumors
Approximately 12 Institutions in the United States and Korea Participate... Clinical Trial Sites to Expand to Europe and Beyond

On April 20, Chong Kun Dang announced that it has begun enrolling the first patient in the United States for the global Phase 1/2a clinical trial of CKD-703, its antibody-drug conjugate (ADC)-based anticancer drug candidate.

This clinical trial targets patients with non-small cell lung cancer (NSCLC) and various solid tumors. It will be conducted at approximately 12 institutions in Korea and the United States, including the MD Anderson Cancer Center in the United States. Starting with the first patient enrollment at the Gabriel Cancer Center in Ohio, the trial aims to determine the safety and maximum tolerated dose (MTD) of CKD-703, as well as to establish the optimal dosage based on proof of concept (POC).

CKD-703 is a drug candidate currently being developed by Chong Kun Dang, applying next-generation ADC platform technology to a monoclonal antibody targeting the hepatocyte growth factor receptor (c-Met) developed in-house. It is an innovative anticancer drug candidate that works by selectively killing only cancer cells. After obtaining approval from the U.S. Food and Drug Administration (FDA) for the Phase 1/2a trial in July last year, the clinical trial plan was also approved by the Ministry of Food and Drug Safety in February this year, enabling patient enrollment to begin in the first half of the year. The company plans to expand clinical trial sites to additional countries such as those in Europe in the future.

A Chong Kun Dang official stated, "The first patient enrollment in the United States is significant as it demonstrates that the global clinical trial of CKD-703 is progressing smoothly."

This content was produced with the assistance of AI translation services.